Abstract
Aim: The aim of the study was to investigate hypoglycemic and hypolipidemic activities of aqueous extracts of Centaurium erythraea (CnE) and Ajuga iva (AjI) after daily oral dosing for 60 days in a rodent model of metabolic syndrome (MetS).
Materials and Methods: Meriones shawi rats were fed a high caloric diet and forced to limited physical activity for 180 days to develop obesity, hyperglycemia and hyperlipidemia (OHH) as a model of MetS. After administration of single oral doses of test substances [extracts of CnE (250 mg/kg) and AjI (150 mg/kg), and reference drug [glibenclamide (GLB; 3 mg/kg)] to OHH rats, plasma levels of glucose, insulin, Total Cholesterol (TC), and Triglycerides (TG) were measured. In the sub-chronic study, the effect of daily oral dosing of test substances for 60 days to OHH rats, on Body Weight (BW), plasma glucose, insulin, TC, Low Density Lipoprotein (LDL)-cholesterol, High Density Lipoprotein (HDL)-cholesterol, TG, and free fatty acids were determined; insulin resistance (IR as HOMA-IR and QUICKI) and atherosclerotic index were calculated. Results and Conclusion: Meriones shawi rats developed OHH, hyperinsulinemia, IR and dyslipidemia- typical components of MetS. Single doses of test substances decreased only hyperglycemia. In the sub-chronic study, the test substances reduced plasma glucose, insulin, TC and LDL-cholesterol, as well as HOMA-IR and atherosclerotic index (AjI-extract > CnE-extract > GLB); plasma level of TG decreased with AjI only. These two plants may have the potential to be used therapeutically in the treatment of diabetes and possibly MetS, since, previous toxicological studies have shown a wide margin of safety for AjI and CnE.Keywords: Ajuga iva, Centaurium erythraea, diabetes, hypoglycemia, hypolipidemia, insulin resistance, Meriones shawi.
The Natural Products Journal
Title:Hypoglycemic and Hypolipidemic Effects of Aqueous Extracts of Ajuga iva and Centaurium erythreae on a Rodent Model of Metabolic Syndrome
Volume: 7 Issue: 1
Author(s): Adel Tahraoui, Zafar H. Israili and Badiaa Lyoussi
Affiliation:
Keywords: Ajuga iva, Centaurium erythraea, diabetes, hypoglycemia, hypolipidemia, insulin resistance, Meriones shawi.
Abstract: Aim: The aim of the study was to investigate hypoglycemic and hypolipidemic activities of aqueous extracts of Centaurium erythraea (CnE) and Ajuga iva (AjI) after daily oral dosing for 60 days in a rodent model of metabolic syndrome (MetS).
Materials and Methods: Meriones shawi rats were fed a high caloric diet and forced to limited physical activity for 180 days to develop obesity, hyperglycemia and hyperlipidemia (OHH) as a model of MetS. After administration of single oral doses of test substances [extracts of CnE (250 mg/kg) and AjI (150 mg/kg), and reference drug [glibenclamide (GLB; 3 mg/kg)] to OHH rats, plasma levels of glucose, insulin, Total Cholesterol (TC), and Triglycerides (TG) were measured. In the sub-chronic study, the effect of daily oral dosing of test substances for 60 days to OHH rats, on Body Weight (BW), plasma glucose, insulin, TC, Low Density Lipoprotein (LDL)-cholesterol, High Density Lipoprotein (HDL)-cholesterol, TG, and free fatty acids were determined; insulin resistance (IR as HOMA-IR and QUICKI) and atherosclerotic index were calculated. Results and Conclusion: Meriones shawi rats developed OHH, hyperinsulinemia, IR and dyslipidemia- typical components of MetS. Single doses of test substances decreased only hyperglycemia. In the sub-chronic study, the test substances reduced plasma glucose, insulin, TC and LDL-cholesterol, as well as HOMA-IR and atherosclerotic index (AjI-extract > CnE-extract > GLB); plasma level of TG decreased with AjI only. These two plants may have the potential to be used therapeutically in the treatment of diabetes and possibly MetS, since, previous toxicological studies have shown a wide margin of safety for AjI and CnE.Export Options
About this article
Cite this article as:
Tahraoui Adel, Israili H. Zafar and Lyoussi Badiaa, Hypoglycemic and Hypolipidemic Effects of Aqueous Extracts of Ajuga iva and Centaurium erythreae on a Rodent Model of Metabolic Syndrome, The Natural Products Journal 2017; 7 (1) . https://dx.doi.org/10.2174/2210315506666161024122601
DOI https://dx.doi.org/10.2174/2210315506666161024122601 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |
Call for Papers in Thematic Issues
Ayurvedic medicinal therapeutic approaches for inflammatory and neurodegenerative disorders
Usually, in our elderly population, neurodegenerative disorders occur due to neuron death. Alzheimer?s disease (AD) is an irreversible and progressive neurodegenerative disease. Dementia is the leading cause of AD, which affects about 30 million people worldwide. According to the World Alzheimer report 2018, a new case of dementia develops every ...read more
Recent Advances in Biotransformation of Bioactive Terpenoids using Aspergillus niger
Biotransformation is the reaction catalyzed by biological catalysts of either isolated enzymes or whole cell cultures of microorganisms. This process has been extensively applied in the conversion of bioactive terpenoids with high regio- and stereospecifity. This process has been also applied in the lead discovery and development. Aspergillus niger has ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sustained Release of Diltiazem Hydrochloride from Chitosan Microcapsules
Current Drug Delivery Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches
Current Medicinal Chemistry Role of Cardiovascular Aldosterone in Hypertension
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Neurodegeneration in the Pathogenesis of Diabetic Retinopathy: Molecular Mechanisms and Therapeutic Implications
Current Medicinal Chemistry Clinical Resolution of Type 2 Diabetes with Reduction in Body Mass Index Using Meal Replacement Based Weight Loss
Vascular Disease Prevention (Discontinued) Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets The Metabolic Syndrome and Vascular Disease in Asia
Cardiovascular & Hematological Disorders-Drug Targets Microdialysis in Drug Discovery
Current Drug Discovery Technologies Calcineurin Inhibition and Development: Insights from Research Models
Current Enzyme Inhibition A Pilot Study on Wet Age Related Macular Degeneration in Chennai and Some Parts of Kerala
Applied Clinical Research, Clinical Trials and Regulatory Affairs Cumulative HIV Viremia Copy-Years and Hypertension in People Living with HIV
Current HIV Research Henoch Schonlein Purpura in Childhood
Current Pediatric Reviews Implications of the Obesity Epidemic for Statin Therapy: Shifting Cholesterol Metabolism to a High Synthesis and Low Dietary Absorption State
Endocrine, Metabolic & Immune Disorders - Drug Targets Analysis of Homocysteine in Plasma of Rats Exposed to High-fat Diet and Chronic Unpredictable Mild Stress by LC/ESI-MS/MS
Current Analytical Chemistry Sodium-Glucose Co-Transporter 2 Inhibitors: From Apple Tree to ‘Sweet Pee’
Current Pharmaceutical Design Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review
Current Cancer Therapy Reviews The Endocrine Function of Adipose Tissue
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Effects of Vitamin E and C on Placental Oxidative Stress: An In Vitro Evidence for the Potential Therapeutic or Prophylactic Treatment of Preeclampsia
Medicinal Chemistry Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study
Current Vascular Pharmacology Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets